NEW YORK (Reuters Health)—The risk of serious infections increases in the early months of anti-TNF treatment for inflammatory bowel disease, researchers from Denmark report. “The pro-inflammatory cytokine TNF-alpha plays an important role in the immune system and therefore it is biologically plausible that TNF-alpha inhibitors may increase the risk of infections,” said Dr. Nynne Nyboe…
Search results for: TNF inhibitors
Anti-TNF Agents May Improve Clinical Symptoms of Ankylosing Spondylitis
Ankylosing spondylitis primarily affects the joints and ligaments of the spine, but may also have an impact on other joints. Patients experience pain and stiffness that limit mobility in the back and other affected joints. Symptoms can come and go, last for long periods of time and be severe. Anti-tumor necrosis factor (anti-TNF) drugs are…
Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis
Physicians at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco report on studies about JAK inhibitors as targeted immunomodulators and disease-modifying therapies in RA
Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors
Two patients with psoriatic arthritis treated with TNF-alpha inhibitor therapy develop the multisystem disease
Tofacitinib and Other Kinase Inhibitors Offer New Approach to Treating Rheumatoid Arthritis
Small molecule kinase inhibitors, such as JAK inhibitors, provide a novel route for rheumatic disease treatment—and may promote our understanding of the immune system’s complexities
ACR Winter Rheumatology Symposium: New Kinase Inhibitors Show Promise
Toxicity and appropriate targeting are challenges for small molecule researchers
Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.
Insights into JAK Inhibitor Use
According to a German study presented during ACR Convergence 2021, treatment persistence with JAK inhibitors is comparable to TNF inhibitors and other bDMARDs among patients with rheumatoid arthritis.
Anti-Drug Antibodies May Affect RA Treatment
A recent study examined the level of anti-drug antibodies (ADAs) in RA patients taking the TNF inhibitors adalimumab, infliximab and etanercept. Study patients without ADAs experienced better clinical outcomes, while patients with detectable ADAs had significantly lower serum trough drug concentrations…
Denosumab Does Not Increase Risk of Infection in RA Patients
New research dispels the fear that denosumab will increase the risk of infection in vulnerable populations with rheumatoid arthritis when it is prescribed in combination with TNF inhibitors or other biologics. Investigators found the treatment did not increase infection risk beyond what is expected for the patients’ disease, comorbidities and medications…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 39
- Next Page »